{
  "run_id": "RUN_20260204_234342_996d5a3920e1",
  "timestamp": "2026-02-05T02:13:27.666114",
  "document": "Glycogen-Storage-Disease-Type-VII.pdf",
  "document_path": "/Users/frederictetard/Projects/ese/gold_data/NLP4RARE/test/Glycogen-Storage-Disease-Type-VII.pdf",
  "pipeline_version": "0.8",
  "total_candidates": 3,
  "total_validated": 3,
  "total_rejected": 0,
  "total_investigational": 0,
  "drugs": [
    {
      "matched_text": "Glycogen",
      "preferred_name": "glycogen",
      "brand_name": null,
      "compound_id": null,
      "confidence": 0.7,
      "is_investigational": false,
      "drug_class": null,
      "mechanism": null,
      "development_phase": null,
      "sponsor": null,
      "conditions": [],
      "nct_id": null,
      "dosage_form": null,
      "route": null,
      "marketing_status": null,
      "codes": {
        "rxcui": null,
        "mesh": "D006003",
        "ndc": null,
        "drugbank": null,
        "unii": null
      },
      "all_identifiers": [
        {
          "system": "RxCUI",
          "code": "1426910",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "D006003",
          "display": "Glycogen"
        }
      ],
      "context": "Glycogen storage diseases are a group of disorders in which stored glycogen cannot be metabolized into glucose to supply energy for the body. Glycogen storage",
      "page": 1,
      "mention_count": 1,
      "pages_mentioned": [
        1
      ],
      "lexicon_source": "2025_08_lexicon_drug.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": "Glycogen",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "phosphofructokinase",
      "preferred_name": "Phosphofructokinase",
      "brand_name": null,
      "compound_id": null,
      "confidence": 0.7,
      "is_investigational": false,
      "drug_class": null,
      "mechanism": null,
      "development_phase": null,
      "sponsor": null,
      "conditions": [],
      "nct_id": null,
      "dosage_form": null,
      "route": null,
      "marketing_status": null,
      "codes": {
        "rxcui": null,
        "mesh": "C027652",
        "ndc": null,
        "drugbank": null,
        "unii": null
      },
      "all_identifiers": [
        {
          "system": "RxCUI",
          "code": "8233",
          "display": null
        },
        {
          "system": "MeSH",
          "code": "C027652",
          "display": "fructose 2 6-diphosphate"
        }
      ],
      "context": "storage disease type VII (GSD VII) is characterized by weakness, pain and stiffness during exercise. GSD VIl is caused by abnormalities in the muscle phosphofructokinase gene that results in a deficiency of the phosphofructokinase enzyme. This enzyme deficiency leads to a reduced amount of energy available to muscles ",
      "page": 1,
      "mention_count": 1,
      "pages_mentioned": [
        1
      ],
      "lexicon_source": "2025_08_lexicon_drug.json",
      "validation_flags": [
        "lexicon_match",
        "pubtator_enriched",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": "fructose 2 6-diphosphate",
      "enrichment_source": "pubtator3"
    },
    {
      "matched_text": "red blood cells",
      "preferred_name": "Red blood cells",
      "brand_name": null,
      "compound_id": null,
      "confidence": 0.7,
      "is_investigational": false,
      "drug_class": null,
      "mechanism": null,
      "development_phase": null,
      "sponsor": null,
      "conditions": [],
      "nct_id": null,
      "dosage_form": null,
      "route": null,
      "marketing_status": null,
      "codes": {
        "rxcui": null,
        "mesh": null,
        "ndc": null,
        "drugbank": null,
        "unii": null
      },
      "all_identifiers": [
        {
          "system": "RxCUI",
          "code": "389304",
          "display": null
        }
      ],
      "context": "VII is diagnosed by a muscle biopsy for measurement of the phosphofructokinase enzyme level or measurement of the phosphofructokinase enzyme level in red blood cells. Molecular genetic testing for the phosphofructokinase gene mutations prevalent in the Ashkenazi Jewish population are available on a research basis.",
      "page": 1,
      "mention_count": 1,
      "pages_mentioned": [
        1
      ],
      "lexicon_source": "2025_08_lexicon_drug.json",
      "validation_flags": [
        "lexicon_match",
        "deduplicated"
      ],
      "mesh_aliases": [],
      "pubtator_normalized_name": null,
      "enrichment_source": null
    }
  ]
}